This study tests a new medicine called ALTO-101T for people with schizophrenia. Schizophrenia is a mental illness that affects how a person thinks, feels, and behaves. In this study, ALTO-101T is compared to a placebo, which is a substance with no active medicine. The study is double-blind, meaning neither the patients nor the doctors know who gets the real medicine or the placebo. The medicine is given through the skin using a transdermal delivery system (TDS), like a patch.

Electroencephalogram (EEG) is a test that records brain activity. The study checks how well ALTO-101T helps thinking processes and measures safety. It also looks at pharmacokinetics (PK), which means how the medicine moves in the body.

• Participation: You must have had schizophrenia for at least one year and be on stable medication.
• Study Duration: Requires visits and tests to track your progress.
• Risks: Cannot join if you have other serious mental disorders or substance use issues.